Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Exelixis Inc (EXEL)  
$22.06 0.03 (0.14%) as of 4:30 Wed 6/12


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 310,240,000
Market Cap: 6.84(B)
Last Volume: 1,347,016 Avg Vol: 2,431,686
52 Week Range: $18.78 - $24.13
Level I Sector: Industrials
Level II Sector: Diversified Services
Level III Sector: Research Services

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    : 17.5
Insider 6 Months    : 18.9
Insider 3/6 Months : 36.8
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 425,000 615,000 735,409 735,409
Total Buy Value $8,733,955 $12,666,689 $15,268,727 $15,268,727
Total People Bought 1 1 1 1
Total Buy Transactions 2 3 4 4
Total Shares Sold 88,818 210,838 601,659 1,021,249
Total Sell Value $1,938,121 $4,689,450 $12,908,109 $20,266,173
Total People Sold 5 7 9 12
Total Sell Transactions 6 9 17 28
End Date 2024-03-14 2023-12-12 2023-06-13 2022-06-13

   
Records found: 1438
  Page 27 of 58  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Poste George Director   –       •      –    2019-03-29 4 AS $23.89 $92,215 D/D (3,860) 102,475     -
   Poste George Director   –       •      –    2019-03-29 4 OE $4.57 $68,550 D/D 15,000 106,335     -
   Morrissey Michael M President and CEO   •       •      –    2019-03-27 4 AS $23.39 $935,600 D/D (40,000) 90,000     -
   Morrissey Michael M President and CEO   •       •      –    2019-03-27 4 OE $5.56 $222,400 D/D 40,000 130,000     -
   Haley Patrick J. Sr. Vice President, Commercial   •       –      –    2019-03-26 4 AS $23.47 $63,369 D/D (2,700) 89,780     -
   Haley Patrick J. Sr. Vice President, Commercial   •       –      –    2019-03-26 4 OE $5.18 $13,986 D/D 2,700 92,480     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2019-03-25 4 AS $23.14 $2,314,000 D/D (100,000) 316,513     -
   Schwab Gisela Md Pres, Prod Dev & Med Aff & CMO   •       –      –    2019-03-25 4 OE $7.18 $718,000 D/D 100,000 416,513     -
   Haley Patrick J. Sr. Vice President, Commercial   •       –      –    2019-03-14 4 AS $25.00 $50,000 D/D (2,000) 89,780     -
   Haley Patrick J. Sr. Vice President, Commercial   •       –      –    2019-03-14 4 OE $1.76 $3,520 D/D 2,000 91,780     -
   Scangos George A Director   –       •      –    2019-03-14 4 AS $25.00 $125,000 D/D (5,000) 1,318,031     -
   Morrissey Michael M President and CEO   •       •      –    2019-03-13 4 AS $24.24 $985,486 D/D (40,000) 90,000     -
   Morrissey Michael M President and CEO   •       •      –    2019-03-13 4 OE $5.56 $222,400 D/D 40,000 130,000     -
   Haley Patrick J. Sr. Vice President, Commercial   •       –      –    2019-03-11 4 AS $23.13 $22,182 D/D (959) 89,780     -
   Scangos George A Director   –       •      –    2019-03-01 4 AS $22.66 $906,400 D/D (40,000) 1,323,031     -
   Morrissey Michael M President and CEO   •       •      –    2019-02-27 4 AS $22.69 $907,600 D/D (40,000) 90,000     -
   Morrissey Michael M President and CEO   •       •      –    2019-02-27 4 OE $5.56 $222,400 D/D 40,000 130,000     -
   Haley Patrick J. Sr. Vice President, Commercial   •       –      –    2019-02-25 4 S $22.27 $95,137 D/D (4,272) 90,739     -
   Cohen Charles Director   –       •      –    2019-02-25 4 S $22.18 $116,911 D/D (5,271) 20,979     -
   Cohen Charles Director   –       •      –    2019-02-25 4 OE $4.16 $115,350 D/D 26,250 26,250     -
   Marchesi Vincent T Director   –       •      –    2019-02-22 4 S $21.50 $886,875 D/D (41,250) 133,850     -
   Marchesi Vincent T Director   –       •      –    2019-02-22 4 OE $4.16 $204,150 D/D 41,250 175,100     -
   Papadopoulos Stelios Director   –       •      –    2019-02-21 4 S $21.25 $557,813 D/D (26,250) 1,042,251     -
   Papadopoulos Stelios Director   –       •      –    2019-02-21 4 OE $4.16 $115,350 D/D 26,250 1,068,501     -
   Willsey Lance Director   –       •      –    2019-02-20 4 S $21.11 $554,138 D/D (26,250) 418,273     -

  1438 Records found
  Previous  20  21  22  23  24  25  26  27  28  29  Next   
  Page 27 of 58
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed